References
- Park JR, Bagatell R, Cohn SL, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting. J Clin Oncol. 2017;35(22):2580–2587. doi:https://doi.org/10.1200/JCO.2016.72.0177.
- Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children’s Oncology Group study P9641. J Clin Oncol. 2012;30(15):1842–1848. doi:https://doi.org/10.1200/JCO.2011.37.9990.
- Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol. 2011;29(4):449–455. doi:https://doi.org/10.1200/JCO.2010.29.5196.
- De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008;99(7):1027–1033. doi:https://doi.org/10.1038/sj.bjc.6604640.
- Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–3017. doi:https://doi.org/10.1200/JCO.2014.59.4648.
- Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. JCO. 2009;27(2):289–297. 2008.16.6785. doi:https://doi.org/10.1200/JCO.
- Greaves M. Leukaemia ‘firsts’ in cancer research and treatment. Nat Rev Cancer. 2016;16(3):163–172. doi:https://doi.org/10.1038/nrc.2016.3.
- Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–424. doi:https://doi.org/10.1038/s41571-019-0187-3.
- Batth IS, Dao L, Satelli A, et al. Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. Int J Cancer. 2020;147(12):3550–3559. doi:https://doi.org/10.1002/ijc.33140.
- Merugu S, Chen L, Gavens E, et al. Detection of circulating and disseminated neuroblastoma cells using the imagestream flow cytometer for use as predictive and pharmacodynamic biomarkers. Clin Cancer Res. 2020;26(1):122–134. doi:https://doi.org/10.1158/1078-0432.CCR-19-0656.
- Morini M, Cangelosi D, Segalerba D, et al. Exosomal microRNAs from longitudinal liquid biopsies for the prediction of response to induction chemotherapy in high-risk neuroblastoma patients: a proof of concept SIOPEN study. Cancers (Basel). 2019; 11(10):1476. doi:https://doi.org/10.3390/cancers11101476.
- Su Y, Wang L, Jiang C, et al. Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma. BMC Cancer. 2020;20(1):102. doi:https://doi.org/10.1186/s12885-020-6562-8.
- Wang X, Wang L, Su Y, et al. Plasma cell-free DNA quantification is highly correlated to tumor burden in children with neuroblastoma. Cancer Med. 2018;7(7):3022–3030. doi:https://doi.org/10.1002/cam4.1586.
- Su Y, Wang L, Wang X, et al. Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma. Cancer Med. 2019;8(4):1558–1566. doi:https://doi.org/10.1002/cam4.2045.
- Su Y, Wang L, Zhao Q, et al. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma. Mol Oncol. 2020;14(11):2884–2893. doi:https://doi.org/10.1002/1878-0261.12794.
- Pattyn A, Morin X, Cremer H, Goridis C, Brunet JF. The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. Nature. 1999;399(6734):366–370. doi:https://doi.org/10.1038/20700.
- Warren M, Matsuno R, Tran H, Shimada H. Utility of Phox2b immunohistochemical stain in neural crest tumours and non-neural crest tumours in paediatric patients. Histopathology. 2018;72(4):685–696. doi:https://doi.org/10.1111/his.13412.
- Hung YP, Lee JP, Bellizzi AM, Hornick JL. PHOX2B reliably distinguishes neuroblastoma among small round blue cell tumours. Histopathology. 2017;71(5):786–794. doi:https://doi.org/10.1111/his.13288.
- Druy AE, Shorikov EV, Tsaur GA, et al. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR. Pediatr Blood Cancer. 2018;65(11):e27354. doi:https://doi.org/10.1002/pbc.27354.
- van Wezel EM, Stutterheim J, Vree F, et al. Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. Pediatr Blood Cancer. 2015;62(8):1368–1373. doi:https://doi.org/10.1002/pbc.25507.
- Tchirkov A, Greze V, Plantaz D, Rouel N, Vago P, Kanold J. Very long-term molecular follow-up of minimal residual disease in patients with neuroblastoma. Pediatr Blood Cancer. 2018;65(12):e27404. doi:https://doi.org/10.1002/pbc.27404.
- Corrias MV, Parodi S, Tchirkov A, et al. Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis. Pediatr Blood Cancer. 2018;65(7):e27052. doi:https://doi.org/10.1002/pbc.27052.
- Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer. 2011;47(8):1193–1202. doi:https://doi.org/10.1016/j.ejca.2011.02.003.
- Hirase S, Saitoh A, Hartomo TB, et al. Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients. Oncol Lett. 2016;12(2):1119–1123. doi:https://doi.org/10.3892/ol.2016.4682.
- Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261(1):243–257. doi:https://doi.org/10.1148/radiol.11101352.
- Li W, Cui L, Gao C, et al. DNMT3A mutations in Chinese childhood acute myeloid leukemia. Medicine (Baltimore, MD ). 2017;96(31):e7620. doi:https://doi.org/10.1097/MD.0000000000007620.
- Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13(6):397–411. doi:https://doi.org/10.1038/nrc3526.
- Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, et al. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol. 2008;26(33):5443–5449. doi:https://doi.org/10.1200/JCO.2007.13.6531.
- Viprey VF, Lastowska MA, Corrias MV, Swerts K, Jackson MS, Burchill SA. Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol. 2008;216(2):245–252. doi:https://doi.org/10.1002/path.2406.
- Dong R, Yang R, Zhan Y, et al. Single-cell characterization of malignant phenotypes and developmental trajectories of adrenal neuroblastoma. Cancer Cell. 2020;38(5):716–733.e6. doi:https://doi.org/10.1016/j.ccell.2020.08.014.
- Burchill SA, Beiske K, Shimada H, et al. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer. 2017;123(7):1095–1105. doi:https://doi.org/10.1002/cncr.30380.
- Follain G, Herrmann D, Harlepp S, et al. Fluids and their mechanics in tumour transit: shaping metastasis. Nat Rev Cancer. 2020;20(2):107–124. doi:https://doi.org/10.1038/s41568-019-0221-x.
- Viprey VF, Gregory WM, Corrias MV, et al. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. J Clin Oncol. 2014;32(10):1074–1083. doi:https://doi.org/10.1200/JCO.2013.53.3604.
- Thwin KKM, Ishida T, Uemura S, et al. Level of seven neuroblastoma-associated mRNAs detected by droplet digital PCR is associated with tumor relapse/regrowth of high-risk neuroblastoma patients. J Mol Diagn. 2020;22(2):236–246. doi:https://doi.org/10.1016/j.jmoldx.2019.10.012.
- Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg. 2012;256(4):573–580. doi:https://doi.org/10.1097/SLA.0b013e31826cbbbd.
- Twist CJ, Schmidt ML, Naranjo A, et al. Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the children’s oncology group study ANBL0531. J Clin Oncol. 2019;37(34):3243–3255. doi:https://doi.org/10.1200/JCO.19.00919.
- Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334. doi:https://doi.org/10.1056/NEJMoa0911123.
- Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363(14):1313–1323. doi:https://doi.org/10.1056/NEJMoa1001527.
- Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298–303. doi:https://doi.org/10.1200/JCO.2008.16.6876.
- Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353(21):2243–2253. doi:https://doi.org/10.1056/NEJMoa052399.
- De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 2019;40(3):172–186. doi:https://doi.org/10.1016/j.tips.2019.01.006.
- Popov A, Druy A, Shorikov E, et al. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma. J Cancer Res Clin Oncol. 2019;145(2):535–542. doi:https://doi.org/10.1007/s00432-018-02831-w.
- Yanez Y, Grau E, Oltra S, et al. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. J Cancer Res Clin Oncol. 2011;137(8):1263–1272. doi:https://doi.org/10.1007/s00432-011-0997-x.
- Greze V, Brugnon F, Chambon F, et al. Highly sensitive assessment of neuroblastoma minimal residual disease in ovarian tissue using RT-qPCR-A strategy for improving the safety of fertility restoration. Pediatr Blood Cancer. 2017;64(5):e26287. doi:https://doi.org/10.1002/pbc.26287.
- Greze V, Kanold J, Chambon F, et al. RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue. Oncol Lett. 2017;14(1):860–866. doi:https://doi.org/10.3892/ol.2017.6238.
- Su Y, Qin H, Chen C, et al. Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China. Pediatric Investigation. 2020;4(3):157–167. doi:https://doi.org/10.1002/ped4.12214.